Nvidia’s Huang Joins Trump’s China Trip as Last-Minute Addition

<figure><img src="https://assets.bwbx.io/images/users/iqjWHBFdfxIU/i9vCCgT2p868/v6/-1x-1.png"><figcaption><div></div><div></div></figcaption></figure><p>&#x201C;Ease of use is what drives adoption,&#x201D; Tandem Diabetes CEO John Sheridan explains to Bloomberg Intelligence about what can fuel further insulin-pump penetration. In this episode of Vanguards of Health Care, Sheridan sits down with BI analyst Matt Henriksson for an in-depth interview about Tandem&#x2019;s Mobi pump, designed for discretion and simplicity, and the AI-powered Control-IQ Plus algorithm, now approved for both type 1 and type 2 diabetes. The conversation also touches on the company&#x2019;s international market strategy, value-based reimbursement and future product development, including the tubeless Sigi.</p><p>Listen to this episode on <a href="https://podcasts.apple.com/us/podcast/vanguards-of-health-care-by-bloomberg-intelligence/id1677173217" title="Link">&lt;meta itemprop="type" content="WebLink"&gt;Apple Podcasts</a> and <a href="https://open.spotify.com/show/6icX87oGAyU53WXglznscG" title="Link">&lt;meta itemprop="type" content="WebLink"&gt;Spotify</a>.</p>

“Ease of use is what drives adoption,” CEO John Sheridan explains to Bloomberg Intelligence about what can drive further insulin pump penetration. In this episode of Vanguards of Health Care, Sheridan sits down with BI analyst Matt Henriksson for an in-depth interview about Tandem’s Mobi pump, designed for discretion and simplicity, and the AI-powered Control-IQ Plus algorithm—now approved for both type 1 and type 2 diabetes who require insulin. The conversation also touches on its international market strategy, value-based reimbursement, and future product development including the tubeless Sigi.

Tandem Diabetes Set to Grow in Type 2: Vanguards of Health Care

Hub Poster

Understand every aspect of the global economy – and know how to make your next move.